ProMIS Neurosciences (PMN) Gains from Investment Securities (2021 - 2024)
ProMIS Neurosciences' (PMN) quarterly Gains from Investment Securities came in at -$59087.0 in Q2 2024, up 90.25% YoY from -$31057.0 in Q3 2023, and down 518.08% on a QoQ basis from $14133.0 in Q1 2024.
ProMIS Neurosciences (PMN) Gains from Investment Securities (2021 - 2024) Analysis & Trends
ProMIS Neurosciences (PMN) has 4 years of Gains from Investment Securities data on file, last reported at -$59087.0 in Q2 2024.
- Quarterly Gains from Investment Securities rose 90.25% year-over-year to -$59087.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$347143.0 (up 81.32% YoY) and the FY2023 annual result came in at -$866738.0, up 44.51% from the prior year.
- Gains from Investment Securities retreated to -$59087.0 in Q2 2024, from $14133.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $41665.0 in Q1 2023 to a low of -$1.2 million in Q4 2022.
- A 4-year average of -$298463.0 and a median of -$119019.0 in 2023 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 117.04% in 2023, down 2515.36% in 2023.
- Tracing PMN's Gains from Investment Securities over 4 years: stood at -$809414.0 in 2021, then slumped by 52.61% to -$1.2 million in 2022, then surged by 85.17% to -$183170.0 in 2023, then jumped by 67.74% to -$59087.0 in 2024.
- The last three Gains from Investment Securities figures came in at -$59087.0 (Q2 2024), $14133.0 (Q1 2024), and -$183170.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -59,087.00 |
| Jun 30, 2024 | -59,087.00 |
| Mar 31, 2024 | 14,133.00 |
| Mar 31, 2024 | 14,133.00 |
| Dec 31, 2023 | -183,170.00 |
| Dec 31, 2023 | -183,170.00 |
| Sep 30, 2023 | -119,019.00 |
| Sep 30, 2023 | -119,019.00 |
| Jun 30, 2023 | -606,214.00 |
| Jun 30, 2023 | -606,214.00 |
| Mar 31, 2023 | 41,665.00 |
| Mar 31, 2023 | 41,665.00 |
| Dec 31, 2022 | -1.24 Mn |
| Dec 31, 2022 | -1.24 Mn |
| Sep 30, 2022 | -58,999.00 |
| Sep 30, 2022 | -58,999.00 |
| Jun 30, 2022 | -23,179.00 |
| Jun 30, 2022 | -23,179.00 |
| Mar 31, 2022 | -244,563.00 |
| Mar 31, 2022 | -244,563.00 |